Clinical studies comparing uroguanylin levels in fasted PD and healthy patients, as well as ligand depletion and uroguanylin overexpression experiments in MPTP mice, are critical to determine whether nigrostriatal GUCY2C is a component of a neuroprotective gut–brain axis. The gene discussed is GUCY2C; the disease is Parkinson disease.